The myeloid-specific transcription factor, CCAAT/enhancer-binding protein ε (C/EBPε) is a critical mediator of myelopoiesis. Mutation of this gene is responsible for neutrophil-specific granule deficiency in humans, a condition that confers susceptibility to Staphylococcus aureus infection. We found that C/EBPε-deficient 
Introduction
Staphylococcus aureus in community and health care settings commonly causes serious and potentially life-threatening infections (1) (2) (3) . Widespread use of antibiotics is responsible for the emergence and rapid spread of resistant pathogens, including methicillin-resistant S. aureus (MRSA) (3) , and highlights a pressing need for development of novel antimicrobial therapies.
Increasingly, novel therapeutics are identified by studying host and bacterial factors that play important roles in the immunopathology of infection. For example, the golden pigment of S.
aureus is an important virulence factor that shields the pathogen from host oxidative killing, and we have previously shown that blocking the biosynthesis of this pigment could be a strategy for treatment of S. aureus infection (4). Conversely, among human genetic conditions that alter susceptibility to S. aureus infection is neutrophil-specific granule deficiency (SGD), a rare hematologic disorder characterized by a significantly defective immunity (5- Genome-wide expression analyses revealed a substantial role for histone deacetylases (HDACs) in the regulation of host defense genes, including complement factors, cytokines, chemokines, and transcriptional regulators (23-27). Also, the activity of the highly conserved family member C/EBPβ is regulated in part by its acetylation and deacetylation (28). Therefore, modification of acetylation could be important for the regulation of the transcription factor C/EBPε and its downstream antimicrobial targets. HDAC inhibitors are essential epigenetic regulators of transcription that modify acetylation of histones and nonhistone proteins (23-27). These inhibitors can block the activity of certain HDACs and induce histone acetylation, leading to the relaxation of chromatin structure with enhanced accessibility of transcriptional machinery to DNA and increased gene transcription (23) (24) (25) . HDAC inhibitors may also induce protein acetylation of transcription factors, resulting in changes in their transcriptional activity and of downstream target genes (26, 27). Nicotinamide (NAM), also referred to as vitamin B3, is the amide of nicotinic acid and is well known to act as a competitive inhibitor of class III HDACs (29-31).
The role of NAM as a modulator of inflammation has been widely reported. For example, NAM is prescribed topically for treatment of a number of inflammatory skin conditions, including acne vulgaris and atopic dermatitis (32). In experimental murine models of Gram-positive and Gramnegative sepsis, NAM has been shown to improve survival (33, 34). The mechanism contributing to immune modulation is not well-defined, but NAM has also been shown to suppress secretion of a number of cytokines and chemokines, including IL-1β, TNF-α, IL-6, and iNOS (35, 36).
Cellular targets of NAM include protein kinase B, forkhead transcription factors, poly(ADP-ribose) polymerase, and cysteine proteases (37). Suppression of the nuclear enzyme poly(ADP-ribose)
polymerase is thought to be potentially important (38, 39), as it contributes to tissue injury by depletion of NAD and by upregulation of inflammatory cytokines and chemokines (40, 41).
More recently, NAM has been shown to induce granulocytosis in human subjects by activation of C/EBPα and G-CSF (42).
Interestingly, despite its implication in a number of host responses, the role of NAM as an antimicrobial agent is limited. NAM has been shown to be effective in amelioration of
Mycobacterium tuberculosis disease in human subjects (43 (Figure 1 , A-C, and Supplemental Figure 1 ). Additionally, s.c.
infection of Cebpe mice was associated with increased systemic spread of bacteria to the spleens and kidneys on day 6 after infection (p.i.; Figure 1C ). Scale bar: 10 εM. Throughout, symbols indicate individual samples, and red bars indicate mean. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 1
Histopathological evaluation with H&E revealed a significantly larger number of neutrophils and macrophages in the skin lesions of Cebpe mice 24 hours p.i. compared with that in WT mice ( Figure 1D and Supplemental Figure 2 ; supplemental material available online with this article; doi: 10.1172/JCI62070DS1), which was accompanied by high levels of the chemokines CXCL1
(also known as KC) and CXCL2 (also known as MIP2) ( Figure 1E ). These data suggest that enhanced accumulation of phagocytic cells at the infection site in Cebpe mice failed to control S. aureus infection and point to the severe defects in the antimicrobial machinery in Cebpe phagocytic cells.
To formally assess the ability of Cebpe phagocytic cells to kill S. aureus, we used a welldescribed phagocytic survival assay, in which peripheral blood from WT and Cebpe mice was infected with S. aureus ex vivo. The assay is commonly used as an approximate measure of neutrophil killing function. As anticipated, bacterial clearance was significantly decreased in the blood of the Cebpe mice compared with that of WT mice ( Figure 1F and Supplemental Figure   3 ). By comparison, overall bacterial clearance by Cebpe bone marrow-derived macrophages
(BMDMs) was not significantly different compared with clearance by WT macrophages ( Figure   1G ). Figure 1H ). By contrast, Cebpe mice depleted of neutrophils showed significantly fewer CFUs within the lesion compared with Cebpe mice with neutrophils ( Figure 1H ), suggesting that C/EBPε deficiency in neutrophils is a major contributor to the severity of infection in the knockout mice. We corroborated this finding using a gentamicin protection assay (intracellular survival assay)
performed on WT and Cebpe whole blood. We showed that S. aureus was readily cleared from WT blood but persisted and grew within cellular elements of Cebpe blood ( Figure 1I , left). In murine infection, H&E staining of infected skin showed Cebpe neutrophils full of intracellular S. aureus. By contrast, only a few intracellular bacteria were found at the lesion site of WT mice ( Figure 1I , right). Taken together, these data suggest that neutrophils from Cebpe mice do not provide an antimicrobial benefit to the host. Notably, in our experiments, we used a NAM concentration of 1 mM, which is similar to the plasma concentration previously measured in humans treated with NAM (47). Importantly, NAM had no direct antistaphylococcal activity when incubated in the absence of phagocytic cells ( Figure 3B and Supplemental Figure 6 ). As a further control, the NAM used in our study has been cell culture tested and was confirmed to be free of endotoxin (pyrogen) (Supplemental Figure 11) . Notably, the shown difference in the clearance of S. aureus by WT and Cebpe blood was more modest in Figure   3D compared with that shown in Figure 1I . This could be attributed to differences in assay condition (standard whole blood assay versus gentamicin protection assay in whole blood): since C/EBPε-related granule proteins play a critical role in the killing of internalized bacteria, adjunctive killing of nonphagocytosed S. aureus by antibiotics, as shown in Figure 1I , could have accentuated the difference between WT and Cebpe blood cell killing.
To test the critical role of C/EBPε in NAM-augmented killing in vivo, we injected WT and 
NAM selectively enhances neutrophil killing of S. aureus. To determine the specific contribution of the myeloid cell lineages to S. aureus clearance in whole blood, we isolated neutrophil and mononuclear fractions from the blood of healthy human volunteers. We pretreated the cells with either PBS or NAM (1 mM) for 24 hours and then measured intracellular survival of S. aureus in each myeloid cell population using a standard gentamicin protection assay. We showed that NAM augmented killing of S. aureus by neutrophils ( Figure 4A and Supplemental Figure 13 ) but not by monocytes ( Figure 4B and Supplemental Figure 14 ). We also evaluated the impact of NAM on macrophage clearance of S. aureus. WT murine BMDMs showed improved killing of S. aureus after NAM treatment (by less than 2 fold; Supplemental Figure 15 ), but the effect was much less dramatic than that observed with neutrophils. Our ex vivo assays suggest that neutrophils are an important target of NAM antimicrobial activity. To investigate the critical role of neutrophils in vivo, we administered control or anti-PMN antibody to WT mice, as previously described above, and then measured S. aureus clearance either with or without NAM treatment. We showed that, in the absence of neutrophils, NAM had no effect on the clearance of S. aureus ( Figure 4C ). It is notable that, in the absence of neutrophils, mice exhibited a higher S. aureus burden that could potentially impact the effect of NAM on bacterial clearance. We repeated the experiment with a 10-to 20-fold lower inoculum and showed that NAM had no effect with the reduced bacterial load (Supplemental Figure 16) .
A previous report showed that administration of NAM to human volunteers can induce C/EBPα and C/EBPβ expression and granulocytosis (42). To determine whether an increased number of circulating neutrophils explains, at least in part, the antimicrobial activity of NAM in our in vivo infection model, we administered either NAM (250 mg/kg) or PBS daily to mice and monitored their changes in myeloid cell populations over 3 days. We showed that under our study conditions, NAM treatment did not induce an increase in myeloid cell populations after 1, 2, or 3 days ( Figure 4D and Supplemental Figure 17 ). Figure 5D ). By contrast, NAM treatment of Cebpe murine neutrophils had no effect on the level of CAMP or 8 7 LTF ( Figure 5D ), suggesting that NAM induction of LTF occurs through the activation of C/EBPε.
We also probed for gp91phox (NOX2) expression and reactive oxygen species production in neutrophils and found that NAM had no impact (Supplemental Figure 21) . We also investigated the effect of NAM on other myeloid cell lineages. We showed that NAM had no impact on C/EBPε, CAMP, and LTF expression in human monocytes ( Figure 5E 
NAM augmented killing of S. aureus in vivo when given after the infectious challenge.
To evaluate whether NAM is beneficial for treatment of an existing infection, we established systemic infection in WT mice with S. aureus for 12 hours prior to commencing daily treatment with NAM ( Figure 6A ). After 60 hours of infection, the number of bacteria recovered from the spleens and kidneys was 30-to 1,000-fold lower in NAM-treated mice compared with that in PBS-treated controls. These data indicate that NAM can be effective against S. aureus whether the compound is administered before or after infection is established. aeruginosa from the blood of healthy human volunteers. Bacterial counts (mean ± SEM) recovered from the peripheral blood of human volunteers (n = 5) after the inoculation with 1.2 × 10 CFU/ml P. aeruginosa (left) or K. pneumoniae (right). *P < 0.05; **P < 0.01; ***P < 0.001.
In line with our data on S. aureus, we also showed that NAM pretreatment of human peripheral blood improved the outcome of infection with other important human pathogens, such as K.
pneumoniae and P. aeruginosa ( Figure 6B ).
Taken together, our findings strongly suggest that increased expression of C/EBPε, induced by the epigenetic modulator NAM, can efficiently enhance the clearance of S. aureus both in vitro and in vivo. human and mouse neutrophils (data not shown). Currently, we do not know which specific antimicrobial or antimicrobial combination downstream of C/EBPε is responsible for the clearance of S. aureus. However, since C/EBPε is known to be an essential regulator for the functional maturation of neutrophils, we speculate that C/EBPε may control a critical antimicrobial program that is inducible by NAM.
Discussion
This program most likely controls specific elements of the neutrophil granules, which include a mixture of cytotoxic enzymes and peptides (e.g., LTF and CAMP), which bear not only a direct but also an indirect antibacterial effect by inducing the expression of cytokines and chemoattractants (54) as well as having a role in antigen presentation (55). It is notable that many neutrophil responses, including chemotaxis, exocytosis, respiratory burst activity, and chemokine synthesis, are mediated by p38MAPK, which is upstream and a direct activator of C/EBPε (56). Therefore, activation of upstream molecules regulating the activity of C/EBPε could be a further mechanism of how NAM exerts its antimicrobial effect. Dissecting the upstream and downstream components of the C/EBPε pathway will be an active area of future studies.
In our study of the myeloid cells, macrophages and monocytes, in comparison to neutrophils, appear to be more modestly impacted by C/EBPε deficiency or by NAM treatment for killing of S.
aureus. Prior studies, however, have shown that C/EBPε-deficient macrophages have reduced expression of a number of immune-related genes (e.g., Il18, Il10, mcp3, and Serpinb2) (16).
We, therefore, speculate that C/EBPε expression in macrophages may still impact clearance of S.
aureus indirectly through cytokine responses. However, neutrophils appear to have a critical role in C/EBPε-mediated responses to S. aureus. Future studies using hematopoietic reconstitution after myeloablative irradiation could directly address the central role of the transcription factor C/EBPε in hematopoietic cells as the critical mediator of S. aureus killing.
An important concern that arises from the study is whether the therapeutic effect documented with S. aureus could be achieved in human subjects using safe NAM doses. In human trials, NAM is frequently administered as a modifier to patients undergoing radiotherapy (47, 48, 57, 58).
In these trials, a plasma concentration of 1 mM NAM is routinely achieved, a concentration that we used in our peripheral whole blood killing assays to demonstrate NAM efficacy. Therefore, our data suggest that a NAM concentration safely achievable in humans could provide protection Our method to measure lesion size has been previously reported (61). Briefly, skin lesions were quantified by multiplying the length and width of the lesion. Irregularly shaped lesions were broken down into smaller symmetrical pieces, and each piece was measured by the same method.
Following euthanization of mice, infected skin lesion tissue was aseptically excised, thoroughly homogenized, and mixed in 1 ml PBS, as previously shown (61). Ten-fold serial dilutions of the homogenates were plated on THA for CFU determination. The spleen and both kidneys were aseptically removed from each animal and processed in the same way. When required, the appropriate homogenized suspensions (skin lesions) were centrifuged at 15,000 g for 10 minutes, and supernatants were stored at -80°C for subsequent analysis by ELISA.
Quantification of neutrophils and macrophages in infected skin lesions. WT and Cebpe mice (n = 8 per group) were infected by s.c. injection of S. aureus at the specified inoculum (see the legend for Figure 1 ) and sacrificed at 24 hours p.i. Infected tissues (skin lesions) were then 
Intracellular survival assay (gentamicin protection assay) in macrophages.
Macrophages were seeded at a density of 5 × 10 cells per well (100 εl) in 96-well tissue culture plates. Macrophages were infected with S. aureus at the specified MOI (see Figure 1G and Figure   2 ). To promote infection, bacteria were spun down onto the macrophages at 500 g for 10 minutes at room temperature, before incubating the cells in a humidified atmosphere at 37°C
and 5% CO . After 30 minutes, macrophages were washed 3 times with prewarmed media to remove extracellular bacteria. Gentamicin (Invitrogen) was then added to each well at a final concentration of 400 εg/ml for 1.5 hours. At this time, the concentration of gentamicin in the media was reduced to 100 εg/ml for the remainder of the assay. At 24 hours p.i., cells were washed 3 times with PBS, then 100 εl of 0.02% Triton X-100 in water was added to each well and pipetted vigorously 10 times to promote macrophage lysis and release intracellular bacteria.
Ten-fold serial dilutions of each cell lysate were immediately plated onto THA, and CFUs were enumerated following overnight incubation at 37°C. Data are representative of at least 2 independent experiments performed in triplicate.
For assays involving PMA-differentiated human U937 macrophages, 24 hours prior to infection, media was replaced without G418 and PMA for the remainder of the time. Zinc (100 μM Zn SO ) was added to the respective pMTε and control groups 24 hours prior to infection and was present for the remainder of the assay.
Neutrophil depletion in vivo. Depletion of neutrophils was carried out as described previously WT and Cebpe mice receiving either anti-mouse PMN antibody or normal serum (control)
were infected s.c. with S. aureus on day 0 (refer to Murine skin infection model). Skin lesion areas were measured daily, and on day 4 (sacrifice) the CFUs in skin lesions, spleens, and kidneys were determined.
To confirm depletion of neutrophils after antibody injection, WT mice (n = 3/group) were sacrificed at day 0 and day 4 of infection. Splenocytes were collected after sacrifice and homogenized, and cells were stained with PE-anti-Ly6G monoclonal antibody and PE.Cy5-antiCD11b monoclonal antibody (eBiosciences). The population of neutrophils (Ly6G , CD11b )
were determined using a CyAnTM flow cytometer (Beckman Coulter), and the data were analyzed by Summit (Dako) software. The total population of neutrophils of mice treated with antibody was highly reduced on day 0 (-72%) and day 4 (-96%; data not shown) compared with that of mice treated with normal serum. Bacteria were pelleted, washed twice, diluted to 1.5 × 10 CFU/ml in 50 εl PBS (without Ca Assessing the effect of NAM on the growth and viability of S. aureus. We assessed whether NAM, at the concentrations used in our study, adversely affect the growth and viability of S. aureus. PBS was chosen as an inert nongrowth medium, and THB was chosen as a suitable growth medium for S. aureus. Seventy-five microliters of NAM (1 mM and 10 mM final concentrations; in either THB or PBS) or THB or PBS alone (respective controls) were placed in sterile 2-ml round-bottom Eppendorf tubes and then inoculated with S. aureus (~1 × 10 CFU/ml in 25 εl of PBS or THB) and immediately briefly vortexed. Triplicate reactions were incubated at 37°C for 1, 3, and 6 hours on a rotary shaker, at which time 10-fold serial dilutions were plated on THA for enumeration of CFUs.
In a different assay, S. aureus (~1 × 10 CFU/ml in THB) was incubated either with or without 50 mM NAM. Triplicate 1-ml reactions were incubated at 37°C on a rotary shaker, and at various time points (6, 12, and 24 hours), 10-fold serial dilutions were plated on THA for enumeration of CFUs. These assays were performed on 3 independent occasions.
Murine and human whole blood assays. This well-described phagocytic survival assay has been previously reported (4). Bacteria were pelleted, washed twice, diluted to the specified inoculum (see the legends for Figures 1, 3 , and 6) in 25 εl PBS (without Ca and Mg ), and immediately mixed with 75 εl of freshly drawn human or murine peripheral whole blood in sterile heparinized 2-ml round-bottom Eppendorf tubes. Reactions (performed in minimum in triplicate)
were incubated at 37°C for 1 to 3 hours on a rotary shaker, at which time 10-fold serial dilutions were plated on THA for enumeration of surviving CFUs.
When required, freshly drawn human or murine peripheral blood was pretreated with NAM (1 mM or 10 mM) or PBS (without Ca and Mg ) prior to inoculation with bacteria. Pretreatment was performed in sterile, nontreated, low evaporation tissue culture plates (Becton Dickinson) for 24 hours in a humidified atmosphere (95% humidity) at 37°C and 5% CO , with gentle mixing on a nutator. On each occasion, blood was aseptically taken from mice via cardiac puncture using a 22-gauge needle to minimize lysis and maintain the integrity of the blood for the duration of the respective assay.
Murine systemic infection. Mice were systemically infected by i.p. injection of ~1 × 10 CFU/ml to 2 × 10 CFU/ml S. aureus for 48 hours. Following euthanasia, the spleen and both kidneys were removed for CFU determination. 37°C and 5% CO . Human monocytes were treated ex vivo with either NAM (1 mM) or PBS for approximately 20 hours and subsequently used for Western blot or functional assays.
Isolation of mouse neutrophils. Isolation of neutrophils from murine whole blood was performed according to a protocol established by Cedarlane Labs. Blood was aseptically collected from mice via cardiac puncture using a 22-gauge needle to minimize lysis and maintain the integrity of the blood cells. Blood was collected in the presence of heparin and used immediately.
rbc were pelleted by centrifugation at 1400 g for 10 minutes at room temperature, without the brake engaged. The buffy coat (wbc layer) and the top layer of the rbc was harvested with a Pasteur pipette and transferred to a fresh tube. PBS (without Ca and Mg ) was added to wash and fully suspend the cells, and the mixture was centrifuged (600 g, 10 minutes, room temperature) to re-pellet the cells. rbc were then lysed using standard protocol. wbc were subsequently resuspended in 4 ml of a serum-free medium (PBS without Ca and Mg ). 4 ml diluted wbc were then carefully layered over 3 ml Lympholyte-Mammal (Cedarlane Labs) at room temperature in a 15-ml centrifuge tube. The gradient was centrifuged at 800 g for 25 minutes at room temperature, without the brake engaged. The resulting interfacial band consisted of lymphocytes, and the pellet consisted of PMNs. Once the PMNs were obtained, further washing was carried out to remove any rbc membranes (rbc ghosts). The majority of the granulocytes were neutrophils (>70%). onto THA using the spread-plate technique (30 ml agar plates to further dilute out any remaining gentamicin), and CFUs were enumerated following overnight incubation at 37°C. A similar assay was performed using human monocytes.
ChIP. The ChIP Assay Kit (Upstate Biotechnology) was used, and chromatin was prepared for immunoprecipitation as instructed by the manufacturer. The sonicated chromatin was immunoprecipitated with either 5 εg anti-acetylated histone H3 antibody or normal rabbit IgG antibody as negative control (Upstate Biotechnology). Immunoprecipitated DNA was subsequently analyzed by PCR using primers specific for the CEBPE promoter region spanning the genomic region -797 to -518 base pairs upstream of the transcriptional start site (position:
21578530; Promoter ID 12948) that was localized by our group (10); input chromatin was analyzed for β-actin mRNA as a positive control. The optimal reaction conditions for PCR were determined for each primer pair. Primers were denatured at 95°C for 1 minute and annealed at 60°C for 1 minute, followed by elongation at 72°C for 1 minute; each product was amplified 35
cycles. PCR products were analyzed by 2.5% agarose/ethidium bromide gel electrophoresis.
Densitometry of all agarose gels was performed using Quantity One software 4.6.3 (Bio-Rad) to quantify fold changes. The primers used for ChIP analysis were as follows: human CEBPE, 5′-GCTTTGGCCAAGCCCAGGGA-3′ (forward), 5′-TGCTGGGCTCCACCTACCCC-3′ (reverse); human ACTB, 5′-CTCCTCGGGAGCCACACGCA-3′ (forward), 5′-TAGGGGAGCTGGCTGGGTGG-3′
(reverse); murine Cebpe, 5′-TGAGGCTGCAGCTTGCCTGG-3′ (forward), 5′-ACCAAGCTACCCCTGGCCCT-3′ (reverse); murine Actb, 5′-ACCTGTTACTTTGGGAGTGGCAAGC-3′
(forward), 5′-GTCGTCCCAGTTGGTAACAATGCC-3′ (reverse).
Western blot and immunoprecipitation. Whole-cell extracts were produced by lysing cells (10 ) with 100 εl denaturing RIPA buffer (50 mM Tris HCl, pH 8; 150 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS) added with a protease inhibitor cocktail (Roche Molecular Biochemicals) on the day of extraction. Extracts were stored at -80°C until use.
For Western blot, protein lysates were boiled in Laemmli sample buffer (Bio-Rad), resolved on 4% to 15% gradient SDS-PAGE gels, and transferred to nitrocellulose membranes (Sigma- We used an anti-acetyl-lysine antibody (ab21623; Abcam) for immunoprecipitation according to the manufacturer's protocol. The input of the protein lysates was used as a loading control.
Statistics. We used 2-tailed unpaired Student's t test to compare 2 independent groups when using ex vivo data; nonparametric Mann-Whitney U test was applied for the independent comparison of the murine in vivo CFU data. One-way ANOVA was used for the comparison of more than 2 independent groups, and 2-way ANOVA, in combination with Bonferroni as post-hoc test, was used to compare murine body weight or lesion size data sets obtained over time.
Paired Student's t test was used for the comparison of human blood samples treated with either NAM or PBS. We deemed a P value below 0.05 as significant. GraphPad Prism was used for analyses. 
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